Jean-noel N. Bastie

Dijon, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

The Impact of Anti-CD38 Monoclonal Antibodies in Frontline Therapy for Patients With Newly Diagnosed Multiple Myeloma: Real-Life Results From the EMMY Study.

The Impact of Anti-CD38 Monoclonal Antibodies in Frontline Therapy for Patients With Newly Diagnosed Multiple Myeloma: Real-Life Results From the EMMY Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: July 03, 2025

Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trial.

Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: May 20, 2025

Assessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed/refractory multiple myeloma: results from the French real-world EMMY study.

Assessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed/refractory multiple myeloma: results from the French real-world EMMY study.

Journal: Haematologica

Published: April 04, 2025

Protein arginine methyltransferase PRMT2 is involved in the control of inflammation in acute myeloid leukemia

Protein arginine methyltransferase PRMT2 is involved in the control of inflammation in acute myeloid leukemia

Journal: Medecine sciences : M/S

Published: December 20, 2024

Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.

Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 17, 2024

Nurturing and growing a community of department heads: Act 2 in haematology

Nurturing and growing a community of department heads: Act 2 in haematology

Journal: Bulletin du cancer

Published: May 03, 2024

Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study.

Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study.

Journal: British journal of haematology

Published: May 02, 2024

Protein arginine methyltransferase 2 controls inflammatory signaling in acute myeloid leukemia.

Protein arginine methyltransferase 2 controls inflammatory signaling in acute myeloid leukemia.

Journal: Communications biology

Published: January 19, 2024

Influence of Sociodemographic Determinants on the Hodgkin Lymphoma Baseline Characteristics in Long Survivors Patients Enrolled in the Prospective Phase 3 Trial AHL2011.

Influence of Sociodemographic Determinants on the Hodgkin Lymphoma Baseline Characteristics in Long Survivors Patients Enrolled in the Prospective Phase 3 Trial AHL2011.

Journal: Cancers

Published: November 19, 2022

Glycemic control in people with diabetes treated with cancer chemotherapy: contribution of continuous glucose monitoring.

Glycemic control in people with diabetes treated with cancer chemotherapy: contribution of continuous glucose monitoring.

Journal: Acta diabetologica

Published: October 25, 2022

Protein Arginine Methyltransferases as Therapeutic Targets in Hematological Malignancies.

Protein Arginine Methyltransferases as Therapeutic Targets in Hematological Malignancies.

Journal: Cancers

Published: October 06, 2022

Early achievement of measurable residual disease negativity in the treatment of multiple myeloma as predictor of outcome.

Early achievement of measurable residual disease negativity in the treatment of multiple myeloma as predictor of outcome.

Journal: British journal of haematology

Published: November 24, 2021

Showing 1-12 of 34

Last Updated: 09/26/2026